Global Assets Advisory LLC Sells 12,550 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Global Assets Advisory LLC reduced its stake in TransMedics Group, Inc. by 84.2%, selling 12,550 shares and now holding only 2,350 shares valued at approximately $306,000.
• TransMedics Group reported earnings of $0.92 per share for the last quarter, significantly exceeding analyst expectations of $0.48, alongside a revenue increase of 37.7% year-over-year.
• Shares of TransMedics Group have seen a 1.5% decline and have a current market cap of $3.88 billion, with a wide range of institutional investors conspicuously involved, holding 99.67% of the stock.

Global Assets Advisory LLC lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 84.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,350 shares of the company's stock after selling 12,550 shares during the quarter. Global Assets Advisory LLC's holdings in TransMedics Group were worth $306,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. OneDigital Investment Advisors LLC boosted its position in TransMedics Group by 52.6% during the first quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company's stock worth $403,000 after purchasing an additional 2,065 shares during the period. Principal Financial Group Inc. lifted its position in shares of TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company's stock worth $13,350,000 after purchasing an additional 5,480 shares during the last quarter. Vontobel Holding Ltd. bought a new position in TransMedics Group in the 1st quarter worth approximately $291,000. New York State Teachers Retirement System lifted its holdings in shares of TransMedics Group by 183.2% during the first quarter. New York State Teachers Retirement System now owns 21,949 shares of the company's stock worth $1,477,000 after buying an additional 14,200 shares during the last quarter. Finally, Peregrine Capital Management LLC boosted its position in shares of TransMedics Group by 3.4% in the first quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company's stock valued at $4,601,000 after acquiring an additional 2,250 shares during the period. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Down 1.5%

Shares of NASDAQ TMDX opened at $113.93 on Tuesday. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $145.50. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The business has a fifty day moving average of $117.18 and a two-hundred day moving average of $111.21. The stock has a market cap of $3.88 billion, a PE ratio of 59.03 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter last year, the company posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on TMDX shares. Zacks Research upgraded shares of TransMedics Group from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 29th. Morgan Stanley upped their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Evercore ISI initiated coverage on TransMedics Group in a research report on Tuesday, September 16th. They set an "outperform" rating and a $155.00 target price on the stock. Oppenheimer upped their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and an average price target of $125.40.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.